NAMPT and in situ carcinoma: For therapeutic purposes, nicotinamide phosphoribosyltransferase inhibitors like FK866 and KPT9274 that are reported to selectively target the EMT subtype (51, 54) could be a substitute for CIS, especially when combined with 5FU, for patients with advanced GC.